Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 136

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Squamous cell carcinoma of skin+2

Not yet recruiting

Efficacy and Safety of Photodynamic Therapy with 5‑Aminolevulinic Acid in Immunosuppressed Patients with Actinic Keratosis and Superficial Basal Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Neoplasm

Not yet recruiting

Long‑term safety of IMA203 and IMA203CD8 autologous T‑cell therapy in patients with previously treated advanced or metastatic solid tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IMA203CD8
  • Sponsor:Immatics US Inc.

Breast cancer+2

Not yet recruiting

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Malignant pleural effusion

Not yet recruiting

Study of Hyperthermic Intrathoracic Chemotherapy with Cisplatin and Pleurectomy versus Standard Care in Patients with Malignant Pleural Effusion

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Universita' Degli Studi Di Torino

Chondrosarcoma+2

Not yet recruiting

Phase I/II Study of Dinutuximab Beta, Irinotecan, and Sirolimus in Children, Adolescents, and Adults with Relapsed or Refractory Bone Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dinutuximab Beta
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Glioblastoma multiforme

Not yet recruiting

Study of autologous mature dendritic cell vaccine plus atezolizumab in patients with recurrent glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Hormone-refractory prostate cancer

Not yet recruiting

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:BioNTech SE

Acute myeloid leukaemia

Not yet recruiting

Fludarabine with drug combination for older or frail patients with acute myeloid leukemia undergoing haploidentical stem cell transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Institut Paoli-Calmettes

Hepatocellular carcinoma

Not yet recruiting

Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Hormone-dependent prostate cancer

Not yet recruiting

Feasibility of Sequential Radium Ra-223 Dichloride After Triplet Therapy in High‑Volume Metastatic Hormone‑Sensitive Prostate Cancer Patients (Phase II)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Radium RA 223 dichloride

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.